Antibody - Pretargeted Cytokine Therapy of Cancer
Abstract
We hypothesize that the selective accumulation of systemically administered cytokines at tumor sites can alter tumor microenvironments to favor the induction of anti-tumor immune responses. We further hypothesize that this can be accomplished by pre-targeting tumors with antibody-streptavidin immunoconjugates and then administering biotinylated cytokines. The purpose of this research program is to identify antibody-pretargeted cytokine therapy strategies that lead to tumor-selective cytokine accumulation, the development of host inflammatory cell infiltrates in tumor, and the induction of tumor-specific immunity. The ultimate goal of this research is to identify candidate strategies for clinical development, alone or in combination with tumor vaccines. We have made significant progress toward achieving these goals. Because biodistribution results did not suggest that the previously used streptavidin-biotin system would yield therapeutic results we have focused efforts in the past year on developing new systems employing bispecific minibodies that contain anti-tumor binding domains and domains that bind to a metal chelate that can serve as a universal acceptor for metal-coniugated cytokines.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2002
- Accession Number
- ADA407653
Entities
People
- Louis M. Weiner
Organizations
- Fox Chase Cancer Center